Patrik Andersson
8PUBLICATIONS
24CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Apr 01, 2026
Integrating transcriptomics and proteomics to assess antisense oligonucleotide safety and efficacy: a time-resolved approach.Daniel van Leeuwen, Miriam Cipullo, Eleanor C Williams
|Jan 21, 2026
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics.Jennifer D Sisler, Patrik Andersson, Alan Brown
|Dec 24, 2025
Apoptotic signatures allow early and rapid screening of drug-induced liver injury to accelerate drug discovery.John Hellgren, Bhavik Chouhan, Aydar Uatay
|Feb 06, 2025
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations.Patrik Andersson, Sebastien A Burel, Heather Estrella
|Jan 23, 2025
Opportunities for More Tailored Approaches to Genotoxicity Testing and Carcinogenicity Strategy for Oligonucleotide Therapeutics: Outcome of an Industry Survey.Joel D Parry, Tod A Harper, Patrik Andersson
|Dec 29, 2022
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides.Aurélie Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke van Roon
Pageof 2
